No Data
No Data
Northeast Pharmaceutical (688076.SH): Oseltamivir phosphate granules for suspension obtained pharmaceutical registration certificate.
Gelonghui, September 25th: Nuotai Biology (688076.SH) announced that the company recently received the "Pharmaceutical Registration Certificate" (Certificate No.: 2024S02238) issued by the National Medical Products Administration for the phosphoric acid oseltamivir dry syrup. Phosphoric acid oseltamivir dry syrup is a pharmaceutical against influenza virus, mainly used for the treatment of Influenza A and B in patients aged 2 weeks and above, as well as for the prevention of Influenza A and B in individuals aged 1 year and above.
Retail Investors Invested in Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHSE:688076) Copped the Brunt of Last Week's CN¥879m Market Cap Decline
gtja: The new signed orders for CXO in the first half of the year show a positive trend, and the API profitability is improving gradually by quarter.
In the first half of the year, CXO performance is under short-term pressure, with a positive trend in new signings; the API destocking is nearing completion, and profitability is improving quarter by quarter.
Nuotai Biology (688076.SH) distributed 0.1 yuan per share in the first half of the year, with a record date of September 9th.
Nutai Biological (688076.SH) announced that the company will distribute interim equity in the first half of 2024, with a dividend of per share...
Jiangsu Sinopep-Allsino Biopharmaceutical's H1 Profit Surges Fivefold
Jiangsu Sinopep-Allsino Biopharmaceutical: Summary of Half-Year Report in 2024.
No Data
No Data